Trials / Terminated
TerminatedNCT00137293
Study Evaluating GAP-486 in Heart Rhythm
A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GAP-486 (ZP-123) | |
| DRUG | 0.9% Sodium Chloride, USP |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-10-01
- First posted
- 2005-08-29
- Last updated
- 2007-12-10
Locations
7 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00137293. Inclusion in this directory is not an endorsement.